Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Renal Cell

Explore clinical trials studying Carcinoma, Renal Cell. Study availability and eligibility vary by location and protocol.

1,363 public trials 252 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Renal Cell trial results

Completed

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +20 more
Locations
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • University of California - San Francisco San Francisco, California, United States
  • Stanford Cancer Institute Stanford, California, United States
  • Yale University New Haven, Connecticut, United States
View all 20 locations
View Trial Details
Completed

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT01631552

Conditions
Adenocarcinoma, Adnexal Diseases, Astrocytoma, +78 more
Locations
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Helen F. Graham Cancer Center Newark, Delaware, United States
  • MD Anderson Cancer Center Orlando (UF Health Cancer Center) Orlando, Florida, United States
View Trial Details
Completed

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

NCT02133742

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • H. Lee Moffitt Cancer Center & Research Institute, Inc. Tampa, Florida, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Brigham & Women's Hospital Boston, Massachusetts, United States
View all 19 locations
View Trial Details
Completed

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

NCT01024920

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +13 more
Locations
  • University of Pecs Medical School, Dept. of Oncotherapy Pécs, Hungary
  • Ziemia Lubelska Oncological Center, Lublin Lublin, Poland
  • Onco.Cent. - Instit. of Maria Sklodowskiej-Curie Warsaw, Poland
  • Military Central Clinical Emergency Hospital Bucharest, Romania
View all 15 locations
View Trial Details
Completed

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

NCT02989714

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
  • University of Minnesota Minneapolis, Minnesota, United States
  • University Hospitals Seidman Cancer Center Cleveland, Ohio, United States
  • Ohio State University Columbus, Ohio, United States
View Trial Details

Related conditions